Subcutaneous IFN-β1a to treat relapsing–remitting multiple sclerosis

References

• Compston A, Confavreux C. The distribution of multiple sclerosis. In: Mc Alpine’s Multiple Sclerosis. Compston A (Ed.). Churchill Livingstone Elsevier Publishers, London, UK, 69–111 (2006).
   Google Scholar
• Ascherio A, Munger KL, Simon KC. Vitamin D and multiple sclerosis. Lancet Neurol. 9(6), 599–612 (2010).
   PubMed Web of Science ®Google Scholar
• Ramagopalan SV, Dobson R, Meier UC, Giovannoni G. Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol. 9(7), 727–739 (2010).
   PubMed Web of Science ®Google Scholar
• Smith K, McDonald I, Miller D, Lassman H. The pathophysiology of multiple sclerosis. In: McAlpine’s Multiple Sclerosis. Compston A (Ed.). Churchill Livingstone Elsevier Publishers, London, UK, 601–659 (2006).
   Google Scholar
• Lassman H, Wekerle H. The pathology of multiple sclerosis. In: Mc Alpine’s Multiple Sclerosis. Compston A (Ed.). Churchill Livingstone Elsevier Publishers, London, UK, 557–599 (2006).
   Google Scholar
• Tintoré M. Rationale for early intervention with immunomodulatory treatments. J. Neurol. 255(Suppl. 1), 37–43 (2008).
   PubMedGoogle Scholar
• Rudick RA, Goelz SE. β-Interferon for multiple sclerosis. Exp. Cell Res. 317(9), 1301–1311 (2011).
   PubMed Web of Science ®Google Scholar
• Racke MK, Lovett-Racke AE. Glatiramer acetate treatment of multiple sclerosis: an immunological perspective. J. Immunol. 186(4), 1887–1890 (2011).
   PubMed Web of Science ®Google Scholar
• Miller DH, Khan OA, Sheremata WA et al.; International Natalizumab Multiple Sclerosis Trial Group. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348(1), 15–23 (2003).
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, O’Connor P et al.; FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 362(5), 387–401 (2010).
   PubMed Web of Science ®Google Scholar
• Le Page E, Leray E, Taurin G et al. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J. Neurol. Neurosurg. Psychiatr. 79(1), 52–56 (2008).
   PubMed Web of Science ®Google Scholar
• van Koetsveld PM, Vitale G, de Herder WW et al. Potent inhibitory effects of Type I interferons on human adrenocortical carcinoma cell growth. J. Clin. Endocrinol. Metab. 91(11), 4537–4543 (2006).
   PubMed Web of Science ®Google Scholar
• Dupont SA, Goelz S, Goyal J, Green M. Mechanisms for regulation of cellular responsiveness to human IFN-β1a. J. Interferon Cytokine Res. 22(4), 491–501 (2002).
   PubMed Web of Science ®Google Scholar
• Oliver-Martos B, Órpez T, Pinto-Medel MJ et al. Gene expression in IFNβ signalling pathway differs between monocytes, CD4 and CD8 T cells from MS patients. J. Neuroimmunol. 230(1–2), 153–159 (2011).
   PubMed Web of Science ®Google Scholar
• PRISMS study group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 352, 1498–1504 (1998).
   Google Scholar
• OWIMS study group. Evidence of interferon β-1a dose response in relapsing–remitting MS. Neurology 53, 679–686 (1999).
   Google Scholar
• The PRISMS study group and the University of British Columbia MS/MIR analysis group. PRISMS-4: long-term efficacy of interferon-β-1a in relapsing MS. Neurology 56, 1628–1636 (2001).
   Google Scholar
• Comi G, Filippi M, Barkhof F et al.; Early Treatment of Multiple Sclerosis Study Group. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357(9268), 1576–1582 (2001).
   PubMed Web of Science ®Google Scholar
• De Stefano N, Polman CH, Uitdehaag BM et al. Comparison of two dosing frequencies of subcutaneous interferon β-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a Phase 3 randomised controlled trial. Lancet Neurol. 11, 33–41 (2012).
   Google Scholar
• Polman CH, Reingold SC, Edan G et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann. Neurol. 58(6), 840–846 (2005).
   PubMed Web of Science ®Google Scholar
• Panitch H, Goodin DS, Francis G et al.; EVIDENCE Study Group. Evidence of Interferon Dose-response: Europian North American Compartative Efficacy; University of British Columbia MS/MRI Research Group. Randomized, comparative study of interferon β-1a treatment regimens in MS: the EVIDENCE trial. Neurology 59(10), 1496–1506 (2002).
   PubMed Web of Science ®Google Scholar
• Schwid SR, Thorpe J, Sharief M et al.; EVIDENCE study group; University of British Columbia MS/MRI Research Group. Enhanced benefit of increasing interferon β-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study. Arch. Neurol. 62(5), 785–792 (2005).
   PubMed Web of Science ®Google Scholar
• Mikol DD, Barkhof F, Chang P et al.; REGARD study group. Comparison of subcutaneous interferon β-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the Rebif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 7(10), 903–914 (2008).
   PubMed Web of Science ®Google Scholar
• SPECTRIMS study group. Randomized controlled trial of interferon- β-1a in secondary progressive MS: clinical results. Neurology 56, 1496–1504 (2001).
   Google Scholar
• Portaccio E, Amato MP. Improving compliance with interferon-β therapy in patients with multiple sclerosis. CNS Drugs 23(6), 453–462 (2009).
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Barbarash O, Casset-Semanaz F et al.; Rebif New Formulation Study Group. Safety and immunogenicity of a new formulation of interferon β-1a (Rebif new formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results. Mult. Scler. 15(2), 219–228 (2009).
   PubMed Web of Science ®Google Scholar
• Camu W, Hadjout K, Latour S, Pöhlau D, Masri S. Patient satisfaction following transition from the original to the new formulation of subcutaneous interferon β-1a in relapsing multiple sclerosis: a randomized, two-arm, open-label, Phase IIIb study. Patient Prefer. Adherence 4, 127–133 (2010).
   PubMed Web of Science ®Google Scholar
• De Stefano N, Curtin F, Stubinski B et al.; IMPROVE Study Investigators. Rapid benefits of a new formulation of subcutaneous interferon β-1a in relapsing–remitting multiple sclerosis. Mult. Scler. 16(7), 888–892 (2010).
   PubMed Web of Science ®Google Scholar
• Sandberg-Wollheim M, Alteri E, Moraga MS, Kornmann G. Pregnancy outcomes in multiple sclerosis following subcutaneous interferon β-1a therapy. Mult. Scler. 17(4), 423–430 (2011).
   PubMed Web of Science ®Google Scholar
• Amato MP, Portaccio E, Ghezzi A et al.; MS Study Group of the Italian Neurological Society. Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis. Neurology 75(20), 1794–1802 (2010).
   PubMed Web of Science ®Google Scholar
• Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J. Chronic Dis. 20(8), 637–648 (1967).
   PubMedGoogle Scholar
• Soilu-Hänninen M, Aivo J, Lindström BM et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1b in patients with multiple sclerosis. J. Neurol. Neurosurg. Psychiatr. 83(5), 565–571 (2012).
   PubMed Web of Science ®Google Scholar